Menu Back toV4-S3

14th DIA Japan Annual Meeting 2017

[V4-S3] What is the Role of Medical Science Liaison (MSL) as New Function of Pharmaceutical Company?

    Session Chair(s)
      Koji  Iwasaki, PhD

      Koji Iwasaki, PhD

      • Professor, Academic Clinical Research Center, Department of Medical Innovation
      • Osaka University Hospital, Japan
    The pharmaceutical companies are starting to establish medical science liaison (MSL) as the new type of job to assume and exchange medical scientific information. In this session, we will discuss an appropriate profit of the drug information about an activity of MSLs In addition to catch the situation of MSL activities in the pharmaceutical company, we will clarify recognition of MSLs by Academia and MHLW. And then we discuss around the future appropriate drug information and the talent of MSLs.
      Masaru  Iwasaki, MD, PhD

      The Role of MSL - Expectation from Academia -

      Masaru Iwasaki, MD, PhD

      • Vice President, Head of Center for Advancing Clinical Research (CACR)
      • University of Yamanashi, Japan
      Yoshihiko  Otoguro

      The Positioning and Activity Principles of MSL -EFPIA Japan-

      Yoshihiko Otoguro

      • Corporate Ethics Working Group, Governance and Legal Committee
      • European Federation of Pharmaceutical Industries and Associations, Japan
      Michiko  Tomiyasu

      MSL: Their Role and What They Should be Equipped for

      Michiko Tomiyasu

      • Manager, Medical Excellence & Training, Medical Affairs
      • Sanofi K.K., Japan
      Yoshifumi  Banzai, PhD

      Expectation to Medical Science Liaison (MSL) in the Utilization of Drug Information from Regulatory Authorities

      Yoshifumi Banzai, PhD

      • Deputy Director, Compliance and Narcotics Division
      • Ministry of Health, Labour and Welfare (MHLW), Japan

Contact us

Please contact the DIA Japan office in Tokyo for further information.

Tel: +81-3-6214-0574
Fax: +81-3-3278-1313